AstraZeneca (NASDAQ:AZN) Shares Unloaded Rep. Lisa C. McClain

Representative Lisa C. McClain (R-Michigan) recently sold shares of AstraZeneca PLC (NASDAQ:AZN). In a filing disclosed on November 21st, the Representative disclosed that they had sold between $1,001 and $15,000 in AstraZeneca stock on October 30th. The trade occurred in the Representative’s “CHARLES SCHWAB BROKERAGE ACCOUNT 924” account.

Representative Lisa C. McClain also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Ciena (NYSE:CIEN) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Alibaba Group (NYSE:BABA) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Coherent (NYSE:COHR) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Clorox (NYSE:CLX) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Northern Trust (NASDAQ:NTRS) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Honda Motor (NYSE:HMC) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Home BancShares (NYSE:HOMB) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Five Below (NASDAQ:FIVE) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of Pure Storage (NYSE:PSTG) on 10/31/2025.
• Sold $1,001 – $15,000 in shares of BHP Group (NYSE:BHP) on 10/31/2025.

AstraZeneca Price Performance

Shares of NASDAQ:AZN traded down $0.72 during midday trading on Friday, reaching $92.60. The company’s stock had a trading volume of 3,747,969 shares, compared to its average volume of 5,153,455. The business’s fifty day simple moving average is $84.55 and its 200-day simple moving average is $77.62. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. AstraZeneca PLC has a fifty-two week low of $61.24 and a fifty-two week high of $94.01. The company has a market capitalization of $287.19 billion, a P/E ratio of 34.81, a P/E/G ratio of 1.52 and a beta of 0.34.

AstraZeneca (NASDAQ:AZN) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.14 by $0.05. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The business had revenue of $15.19 billion for the quarter, compared to the consensus estimate of $14.75 billion. During the same quarter in the prior year, the company earned $2.08 EPS. The firm’s quarterly revenue was up 12.0% on a year-over-year basis. As a group, equities research analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

AZN has been the topic of a number of research reports. Weiss Ratings reiterated a “buy (b)” rating on shares of AstraZeneca in a research report on Wednesday, October 8th. Deutsche Bank Aktiengesellschaft cut shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Thursday, October 16th. Finally, Jefferies Financial Group initiated coverage on AstraZeneca in a research report on Monday, October 27th. They issued a “buy” rating on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Hedge Funds Weigh In On AstraZeneca

Large investors have recently bought and sold shares of the business. Goldman Sachs Group Inc. grew its holdings in AstraZeneca by 30.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company’s stock worth $1,003,124,000 after acquiring an additional 3,224,251 shares during the period. Bank of Montreal Can grew its stake in shares of AstraZeneca by 344.6% during the third quarter. Bank of Montreal Can now owns 3,478,114 shares of the company’s stock worth $266,841,000 after purchasing an additional 2,695,793 shares during the period. Fayez Sarofim & Co increased its holdings in AstraZeneca by 173.4% in the second quarter. Fayez Sarofim & Co now owns 3,745,902 shares of the company’s stock valued at $261,764,000 after purchasing an additional 2,376,032 shares during the last quarter. Valeo Financial Advisors LLC lifted its stake in AstraZeneca by 14,797.3% in the second quarter. Valeo Financial Advisors LLC now owns 2,322,638 shares of the company’s stock valued at $162,306,000 after buying an additional 2,307,047 shares during the period. Finally, Acadian Asset Management LLC lifted its stake in AstraZeneca by 2,389.9% in the second quarter. Acadian Asset Management LLC now owns 2,043,850 shares of the company’s stock valued at $142,798,000 after buying an additional 1,961,764 shares during the period. 20.35% of the stock is currently owned by institutional investors and hedge funds.

About Representative McClain

Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan’s 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.

McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan’s 9th Congressional District. She declared candidacy for the 2026 election.

Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor’s degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.